Rovin Capital UT ADV Acquires 101 Shares of Thermo Fisher Scientific Inc. $TMO

Rovin Capital UT ADV grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.0% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 820 shares of the medical research company’s stock after acquiring an additional 101 shares during the quarter. Rovin Capital UT ADV’s holdings in Thermo Fisher Scientific were worth $332,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Nuveen LLC acquired a new position in Thermo Fisher Scientific during the first quarter valued at approximately $532,360,000. EdgePoint Investment Group Inc. acquired a new position in shares of Thermo Fisher Scientific during the 1st quarter worth $172,139,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Thermo Fisher Scientific by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company’s stock worth $1,368,859,000 after buying an additional 329,974 shares during the last quarter. Auto Owners Insurance Co grew its holdings in Thermo Fisher Scientific by 6,773.5% during the 1st quarter. Auto Owners Insurance Co now owns 288,000 shares of the medical research company’s stock worth $143,309,000 after acquiring an additional 283,810 shares during the last quarter. Finally, Alliancebernstein L.P. increased its stake in shares of Thermo Fisher Scientific by 18.3% in the first quarter. Alliancebernstein L.P. now owns 1,766,067 shares of the medical research company’s stock valued at $878,795,000 after buying an additional 272,747 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have commented on TMO. Robert W. Baird upped their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a research report on Thursday, July 24th. Raymond James Financial reissued an “outperform” rating and issued a $535.00 price target (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Wells Fargo & Company increased their price target on shares of Thermo Fisher Scientific from $565.00 to $635.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. Barclays raised their price target on Thermo Fisher Scientific from $585.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Finally, Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. Nineteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $601.65.

Insiders Place Their Bets

In other news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $574.15, for a total transaction of $229,660.00. Following the sale, the executive vice president directly owned 21,152 shares of the company’s stock, valued at $12,144,420.80. The trade was a 1.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 36,420 shares of company stock worth $19,980,884 over the last 90 days. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.2%

NYSE TMO opened at $566.47 on Friday. The stock has a 50 day moving average price of $516.99 and a 200-day moving average price of $461.35. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. The company has a market capitalization of $212.83 billion, a P/E ratio of 32.73, a P/E/G ratio of 3.27 and a beta of 0.82.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. During the same quarter in the prior year, the firm posted $5.28 EPS. Thermo Fisher Scientific’s quarterly revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.94%.

Thermo Fisher Scientific announced that its board has initiated a share repurchase plan on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 2.4% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.